- Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment
-
Ahn YJ, Hwang HB, Chung SK
- KMID: 1792113
- Korean J Ophthalmol.
- 2014 Apr;28(2):177-180.
- doi: 10.3341/kjo.2014.28.2.177
Vascular endothelial growth factor inhibitor is an emerging therapeutic modality for various ocular diseases with neovascularization (NV). However, for corneal NV, controversy remains regarding whether bevacizumab or ranibizumab is superior.... -
- CITED
-
- Close
- SHARE
-
- Close
